Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
26.20 +1.70 (+6.94%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 26.38 +0.18 (+0.69%) 19:59 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
24.26
Day High
26.24
Open 24.69
Previous Close 24.50 24.50
Volume 11,006,101 11,006,101
Avg Vol 10,151,890 10,151,890
Stochastic %K 22.53% 22.53%
Weighted Alpha -76.58 -76.58
5-Day Change +1.09 (+4.34%) +1.09 (+4.34%)
52-Week Range 23.15 - 170.47 23.15 - 170.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,129,522
  • Shares Outstanding, K 386,623
  • Annual Sales, $ 3,236 M
  • Annual Income, $ -3,561 M
  • EBIT $ -3,945 M
  • EBITDA $ -3,851 M
  • 60-Month Beta 2.23
  • Price/Sales 2.93
  • Price/Cash Flow N/A
  • Price/Book 0.86

Options Overview Details

View History
  • Implied Volatility 92.68% ( -1.58%)
  • Historical Volatility 80.39%
  • IV Percentile 98%
  • IV Rank 81.07%
  • IV High 104.55% on 04/08/25
  • IV Low 41.88% on 05/17/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 162,095
  • Volume Avg (30-Day) 80,799
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 858,035
  • Open Int (30-Day) 821,194

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -2.91
  • Number of Estimates 10
  • High Estimate -1.26
  • Low Estimate -3.64
  • Prior Year -3.07
  • Growth Rate Est. (year over year) +5.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.15 +13.17%
on 04/07/25
Period Open: 33.76
38.12 -31.27%
on 03/13/25
-7.56 (-22.39%)
since 03/11/25
3-Month
23.15 +13.17%
on 04/07/25
Period Open: 42.25
45.40 -42.29%
on 01/24/25
-16.05 (-37.99%)
since 01/10/25
52-Week
23.15 +13.17%
on 04/07/25
Period Open: 107.01
170.47 -84.63%
on 05/24/24
-80.81 (-75.52%)
since 04/11/24

Most Recent Stories

More News
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling

Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.

NVAX : 5.86 (+7.92%)
MRNA : 26.20 (+6.94%)
PFE : 21.91 (+1.48%)
BNTX : 96.52 (+3.65%)
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its...

MRNA : 26.20 (+6.94%)
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

TXG : 8.01 (+4.03%)
PACB : 1.3600 (-1.45%)
HIMS : 27.23 (+1.57%)
MRNA : 26.20 (+6.94%)
Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the...

COMP : 7.51 (+0.40%)
MRNA : 26.20 (+6.94%)
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

BMRN : 56.82 (+0.89%)
VRTX : 484.22 (+1.84%)
MRNA : 26.20 (+6.94%)
UTHR : 281.16 (+0.81%)
BIIB : 115.17 (+1.58%)
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza,...

MRNA : 26.20 (+6.94%)
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) . These two vaccine makers made...

MRNA : 26.20 (+6.94%)
PFE : 21.91 (+1.48%)
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

SRPT : 51.03 (+1.43%)
BMRN : 56.82 (+0.89%)
VRTX : 484.22 (+1.84%)
MRNA : 26.20 (+6.94%)
AMGN : 285.98 (+1.62%)
FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?

Moderna (NASDAQ: MRNA) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later...

MRNA : 26.20 (+6.94%)
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV vaccine, Abrysvo. The vaccine has been approved for the prevention of lower...

MRNA : 26.20 (+6.94%)
GSK : 34.64 (+3.10%)
PFE : 21.91 (+1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 28.85
2nd Resistance Point 27.55
1st Resistance Point 26.87
Last Price 26.20
1st Support Level 24.89
2nd Support Level 23.59
3rd Support Level 22.91

See More

52-Week High 170.47
Fibonacci 61.8% 114.19
Fibonacci 50% 96.81
Fibonacci 38.2% 79.43
Last Price 26.20
52-Week Low 23.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar